Dujardin Makeda
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Dujardin Makeda has a total of 52 co-authors. Here are the top co-authors by number of shared publications:
- Hermann Yokolo
Faculty of Medicine Université Libre des Pays des Grands Lacs Goma DR Congo
22 shared publications - Joshua Ekouo
Faculty of Medicine Université Libre des Pays des Grands Lacs Goma DR Congo
22 shared publications - Christian Tague
Université Libre Des Pays Des Grands Lacs Goma DR Congo
21 shared publications - Aymar Akilimali
Faculty of Medicine University of Goma Goma DR Congo
17 shared publications - Elie Kihanduka
Department of Research, Medical Research Circle (MedReC), Goma, DR Congo
6 shared publications - Jones Onesime
Department of research, Medical Research Circle (MedReC), Goma, Democratic Republic of the Congo
5 shared publications
Latest Publications
- Open Access
- 22 September 2026
- Published by Wiley in Health Science Reports
- Vol. 9 (10) , e73278
Role of Triceps Muscle Fiber‐Specific Myokines in Pancreatic β‐Cell Protection: Implications for Type 2 Diabetes: A Narrative Review
Background and Aims: Type 2 diabetes (T2D) is a major global health challenge, primarily driven by insulin resistance and progressive β‐cell dysfunction aggravated by chronic low‐grade inflammation. Skeletal muscle has emerged as a pivotal endocrine organ through the secretion of myokines, which exert systemic metabolic and immunomodulatory effects. Methods: This narrative review was conducted through systematic database searches (PubMed, Scopus, Web of Science, Google Scholar) using predefined keywords related to myokines, type 2 diabetes, β‐cell survival, and triceps brachii. Publications from 2010 to 2025 were included based on scientific relevance and thematic suitability. Results: Among known myokines, irisin, FGF21, IL‐6, and IL‐15 demonstrate beneficial actions on glucose homeostasis, insulin sensitivity, and β‐cell survival. Evidence suggests that muscle fiber type composition may influence myokine secretion patterns, with type II fibers, predominant in the triceps brachii, producing distinct bioactive profiles. Notably, angiogenin and osteoprotegerin, associated with type II fiber activity, display cytoprotective effects on pancreatic β‐cells by reducing oxidative stress, modulating inflammation, and inhibiting apoptosis. Conflicting data exist, as the type II fiber secretome can also be pro‐inflammatory under metabolic stress conditions. Conclusion: Triceps‐targeted resistance exercises could represent a promising non‐pharmacological strategy to enhance protective myokine release, complementing conventional diabetes management. Nevertheless, most available data derive from preclinical studies, and translational evidence in humans remains scarce. Future research should prioritize longitudinal and interventional studies to validate these findings, assess interindividual variability, and explore therapeutic applications of type II fiber‐associated myokines.
- 22 September 2026
- Published by Wiley in Health Science Reports
- Vol. 9 (10) , e73278
Open AccessRole of Triceps Muscle Fiber‐Specific Myokines in Pancreatic β‐Cell Protection: Implications for Type 2 Diabetes: A Narrative Review
Background and Aims: Type 2 diabetes (T2D) is a major global health challenge, primarily driven by insulin resistance and progressive β‐cell dysfunction aggravated by chronic low‐grade inflammation. Skeletal muscle has emerged as a pivotal endocrine organ through the secretion of myokines, which exert systemic metabolic and immunomodulatory effects. Methods: This narrative review was conducted through systematic database searches (PubMed, Scopus, Web of Science, Google Scholar) using predefined keywords related to myokines, type 2 diabetes, β‐cell survival, and triceps brachii. Publications from 2010 to 2025 were included based on scientific relevance and thematic suitability. Results: Among known myokines, irisin, FGF21, IL‐6, and IL‐15 demonstrate beneficial actions on glucose homeostasis, insulin sensitivity, and β‐cell survival. Evidence suggests that muscle fiber type composition may influence myokine secretion patterns, with type II fibers, predominant in the triceps brachii, producing distinct bioactive profiles. Notably, angiogenin and osteoprotegerin, associated with type II fiber activity, display cytoprotective effects on pancreatic β‐cells by reducing oxidative stress, modulating inflammation, and inhibiting apoptosis. Conflicting data exist, as the type II fiber secretome can also be pro‐inflammatory under metabolic stress conditions. Conclusion: Triceps‐targeted resistance exercises could represent a promising non‐pharmacological strategy to enhance protective myokine release, complementing conventional diabetes management. Nevertheless, most available data derive from preclinical studies, and translational evidence in humans remains scarce. Future research should prioritize longitudinal and interventional studies to validate these findings, assess interindividual variability, and explore therapeutic applications of type II fiber‐associated myokines.
- Open Access
- 3 July 2026
- Published by Wiley in Public Health Challenges
- Vol. 5 (3) , e70311
Pediatric Tuberculosis in North Kivu: The Urgency of a Targeted Response to a Forgotten Childhood Disease
Pediatric tuberculosis remains a neglected health emergency, particularly in fragile contexts such as North Kivu province in the Democratic Republic of Congo. While more than one million children contract tuberculosis each year worldwide, the majority of cases remain underdiagnosed, resulting in preventable morbidity and mortality. In North Kivu, armed conflict, massive displacement, chronic malnutrition, overcrowding, and a weak health system create fertile ground for the spread of tuberculosis and complicate child care. Limited access to diagnostic tools (radiography, GeneXpert), insufficient Bacillus Calmette–Guérin (BCG) vaccination coverage, and a lack of appropriate pediatric drug formulations exacerbate the situation. National and international tuberculosis control strategies remain largely focused on adults, leaving children on the margins of policies and interventions. This editorial calls for an urgent and targeted response, including active contact tracing, improved access to diagnostic tools, the availability of appropriate medications, community outreach, and the involvement of humanitarian actors. Coordinated and context‐specific action is essential to ensure that children in North Kivu no longer remain the invisible victims of a preventable and curable disease.
- 3 July 2026
- Published by Wiley in Public Health Challenges
- Vol. 5 (3) , e70311
Open AccessPediatric Tuberculosis in North Kivu: The Urgency of a Targeted Response to a Forgotten Childhood Disease
Pediatric tuberculosis remains a neglected health emergency, particularly in fragile contexts such as North Kivu province in the Democratic Republic of Congo. While more than one million children contract tuberculosis each year worldwide, the majority of cases remain underdiagnosed, resulting in preventable morbidity and mortality. In North Kivu, armed conflict, massive displacement, chronic malnutrition, overcrowding, and a weak health system create fertile ground for the spread of tuberculosis and complicate child care. Limited access to diagnostic tools (radiography, GeneXpert), insufficient Bacillus Calmette–Guérin (BCG) vaccination coverage, and a lack of appropriate pediatric drug formulations exacerbate the situation. National and international tuberculosis control strategies remain largely focused on adults, leaving children on the margins of policies and interventions. This editorial calls for an urgent and targeted response, including active contact tracing, improved access to diagnostic tools, the availability of appropriate medications, community outreach, and the involvement of humanitarian actors. Coordinated and context‐specific action is essential to ensure that children in North Kivu no longer remain the invisible victims of a preventable and curable disease.
- Open Access
- 10 June 2026
- Published by Wiley in Health Science Reports
- Vol. 9 (6) , e72659
The Rising Burden of Osteosarcopenia in Older Adults: A Narrative Review of Pathophysiology, Diagnostic Challenges, and Therapeutic Perspectives
Background and Aims: Osteosarcopenia, defined as the coexistence of osteoporosis and sarcopenia, is an emerging geriatric syndrome linked to the musculoskeletal decline associated with aging. It is correlated with an increased risk of falls, fractures, disability, and mortality. This review aims to synthesize the emerging concepts, underlying mechanisms, epidemiology, diagnostic challenges, and current therapeutic strategies for osteosarcopenia. Methods: A narrative review was conducted using the PubMed, Scopus, and Google Scholar databases. The keywords used were: osteosarcopenia, sarcopenia, osteoporosis, frailty, and related terms. Relevant peer‐reviewed studies and reports from international organizations were included. The selected articles, addressing definitions, pathophysiology, epidemiology, diagnosis, and management, underwent thematic analysis. Results: Osteosarcopenia affects approximately 18% to 20% of older adults. Its prevalence increases with age and is higher in women. Osteosarcopenia results from mechanisms common to both bones and muscles, including chronic inflammation, hormonal decline, genetic and epigenetic factors, dysregulated signaling pathways, and the interplay between muscles and bones. Risk factors include age, sedentary lifestyle, malnutrition, chronic diseases, and endocrine disorders. Diagnosis remains complex due to the lack of standardized criteria and relies on separate assessments such as bone densitometry (DXA) for bone density and functional tests for muscle strength. The emergence of biomarkers and composite indices holds promise for improved detection. Management primarily involves resistance training, nutritional optimization (protein, calcium, vitamin D), and anti‐osteoporosis medications. However, no treatment simultaneously targets both components, and pharmacological options remain limited. Conclusion: Osteosarcopenia represents a major and growing public health problem in aging populations. Despite progress in understanding its pathophysiology, gaps persist in standardized diagnosis and integrated treatment. Multidisciplinary approaches combining physical exercise, nutrition, and pharmacotherapy, as well as future research on unified diagnostic criteria and targeted therapies, are essential to reduce its impact and improve the functional abilities of older adults.
- 10 June 2026
- Published by Wiley in Health Science Reports
- Vol. 9 (6) , e72659
Open AccessThe Rising Burden of Osteosarcopenia in Older Adults: A Narrative Review of Pathophysiology, Diagnostic Challenges, and Therapeutic Perspectives
Background and Aims: Osteosarcopenia, defined as the coexistence of osteoporosis and sarcopenia, is an emerging geriatric syndrome linked to the musculoskeletal decline associated with aging. It is correlated with an increased risk of falls, fractures, disability, and mortality. This review aims to synthesize the emerging concepts, underlying mechanisms, epidemiology, diagnostic challenges, and current therapeutic strategies for osteosarcopenia. Methods: A narrative review was conducted using the PubMed, Scopus, and Google Scholar databases. The keywords used were: osteosarcopenia, sarcopenia, osteoporosis, frailty, and related terms. Relevant peer‐reviewed studies and reports from international organizations were included. The selected articles, addressing definitions, pathophysiology, epidemiology, diagnosis, and management, underwent thematic analysis. Results: Osteosarcopenia affects approximately 18% to 20% of older adults. Its prevalence increases with age and is higher in women. Osteosarcopenia results from mechanisms common to both bones and muscles, including chronic inflammation, hormonal decline, genetic and epigenetic factors, dysregulated signaling pathways, and the interplay between muscles and bones. Risk factors include age, sedentary lifestyle, malnutrition, chronic diseases, and endocrine disorders. Diagnosis remains complex due to the lack of standardized criteria and relies on separate assessments such as bone densitometry (DXA) for bone density and functional tests for muscle strength. The emergence of biomarkers and composite indices holds promise for improved detection. Management primarily involves resistance training, nutritional optimization (protein, calcium, vitamin D), and anti‐osteoporosis medications. However, no treatment simultaneously targets both components, and pharmacological options remain limited. Conclusion: Osteosarcopenia represents a major and growing public health problem in aging populations. Despite progress in understanding its pathophysiology, gaps persist in standardized diagnosis and integrated treatment. Multidisciplinary approaches combining physical exercise, nutrition, and pharmacotherapy, as well as future research on unified diagnostic criteria and targeted therapies, are essential to reduce its impact and improve the functional abilities of older adults.
- Open Access
- 1 May 2026
- Published by Elsevier in Vaccine: X
- Vol. 30
Hepatitis B vaccination coverage and epidemiological impact on liver cancer in Central Africa
- 1 May 2026
- Published by Elsevier in Vaccine: X
- Vol. 30
Open AccessHepatitis B vaccination coverage and epidemiological impact on liver cancer in Central Africa
- Open Access
- 29 March 2026
- Published by Wiley in Health Science Reports
- Vol. 9 (4)
Triple Burden in the Democratic Republic of Congo: Climate Change, Armed Conflict, and the Silent Spread of Arboviruses. A Narrative Review
Background: The Democratic Republic of Congo (DRC) faces a “triple burden” of public health threats which includes climate change, protracted armed conflict, and the under‐recognized spread of arboviral diseases. Arboviruses, such as dengue, chikungunya, Zika, and yellow fever, are transmitted by Aedes aegypti and Aedes albopictus mosquitoes. Certain factors, like environmental changes, population displacement, and inadequate vector control, have created conditions that favor sustained transmission. Methods: The narrative review was conducted to compile evidence on factors influencing arbovirus spread in the DRC and to identify the priority causes of prevention. A comprehensive literature search was done in PubMed and Google Scholar for studies, NGO reports, and government documents published between 2019 and 2025 in French or English, focusing on human populations in the DRC or similar contexts. Results: Key findings demonstrate that yellow fever remains endemic, with recurrent outbreaks and a case fatality rate of up to 21.3% in past years. Seroprevalence studies show significant dengue exposure (up to 41% in Kinshasa), multiple chikungunya epidemics which affected millions, and intermittent Zika virus exposure. On the other hand, adverse climate change alters vector ecology and increases transmission potential through drought, floods, rising temperatures, and deforestation. Armed conflict proved to play a major role in the large‐scale displacement of people into overcrowded, unsanitary environments. This, as a result, disrupts the surveillance and control programmes and increases vulnerability to arboviruses. Conclusion: The convergence of climate change, armed conflict, and arbovirus transmission poses a growing public health threat in the DRC. Strengthening integrated and reinforced surveillance, augmenting diagnostic capacity, applying sustainable vector control, and advocating climate and security considerations in health policy are essential and mandatory. Without coordinated and multidisciplinary action, the silent and hazardous spread of arboviruses will remain consistent to weaken and compromise health system resilience.
- 29 March 2026
- Published by Wiley in Health Science Reports
- Vol. 9 (4)
Open AccessTriple Burden in the Democratic Republic of Congo: Climate Change, Armed Conflict, and the Silent Spread of Arboviruses. A Narrative Review
Background: The Democratic Republic of Congo (DRC) faces a “triple burden” of public health threats which includes climate change, protracted armed conflict, and the under‐recognized spread of arboviral diseases. Arboviruses, such as dengue, chikungunya, Zika, and yellow fever, are transmitted by Aedes aegypti and Aedes albopictus mosquitoes. Certain factors, like environmental changes, population displacement, and inadequate vector control, have created conditions that favor sustained transmission. Methods: The narrative review was conducted to compile evidence on factors influencing arbovirus spread in the DRC and to identify the priority causes of prevention. A comprehensive literature search was done in PubMed and Google Scholar for studies, NGO reports, and government documents published between 2019 and 2025 in French or English, focusing on human populations in the DRC or similar contexts. Results: Key findings demonstrate that yellow fever remains endemic, with recurrent outbreaks and a case fatality rate of up to 21.3% in past years. Seroprevalence studies show significant dengue exposure (up to 41% in Kinshasa), multiple chikungunya epidemics which affected millions, and intermittent Zika virus exposure. On the other hand, adverse climate change alters vector ecology and increases transmission potential through drought, floods, rising temperatures, and deforestation. Armed conflict proved to play a major role in the large‐scale displacement of people into overcrowded, unsanitary environments. This, as a result, disrupts the surveillance and control programmes and increases vulnerability to arboviruses. Conclusion: The convergence of climate change, armed conflict, and arbovirus transmission poses a growing public health threat in the DRC. Strengthening integrated and reinforced surveillance, augmenting diagnostic capacity, applying sustainable vector control, and advocating climate and security considerations in health policy are essential and mandatory. Without coordinated and multidisciplinary action, the silent and hazardous spread of arboviruses will remain consistent to weaken and compromise health system resilience.
- Open Access
- 1 January 2026
- Published by Wiley in Journal of Tropical Medicine
- Vol. 2026 (1)
Malaria Elimination in Suriname, Timor‐Leste and Georgia: Strategic Lessons for Sub‐Saharan Africa
Background: Malaria remains a major cause of morbidity and mortality worldwide, with over 263 million cases and 597,000 deaths estimated in 2023, of which 94% occurred in Sub‐Saharan Africa. Despite this heavy burden, several low‐ and middle‐income countries have recently succeeded in eliminating local malaria transmission. Objective: This article describes and synthesises malaria elimination experiences in Suriname, Timor‐Leste and Georgia, all three certified malaria‐free by the World Health Organization in 2025, to identify strategic lessons and contextual factors that may inform elimination efforts in malaria‐endemic countries, including those in Sub‐Saharan Africa. Methodology: A structured narrative review was conducted using official reports from WHO, the Global Fund and PAHO; national public health documents; and peer‐reviewed articles indexed in PubMed, Scopus and Google Scholar between 2012 and 2025. Search terms included ‘malaria elimination,’ ‘malaria‐free certification,’ ‘Suriname malaria,’ ‘Timor‐Leste malaria’ and ‘Georgia malaria.’ Inclusion criteria required relevance to elimination strategies, publication in English or French and availability in full text. Grey literature from WHO, PAHO and the Global Fund was systematically included. Results: The three countries share several common determinants of success: strong and sustained political commitment, robust epidemiological surveillance systems, active community mobilisation and consistent financial support. Strategies were adapted to context: involvement of indigenous communities and cross‐border control in the Amazon basin (Suriname), universal coverage and extensive partner support in a postconflict setting (Timor‐Leste) and institutional resilience and postelimination vigilance in a context of political transition (Georgia). Conclusion: These experiences demonstrate that malaria elimination is achievable even in resource‐limited or fragile contexts, provided interventions are tailored to the local setting and supported by coherent governance. Key lessons for malaria‐endemic countries include strengthening community‐based surveillance, cross‐border cooperation, community education and securing sustainable financing. The risk of reintroduction remains real, and postelimination vigilance is essential.
- 1 January 2026
- Published by Wiley in Journal of Tropical Medicine
- Vol. 2026 (1)
Open AccessMalaria Elimination in Suriname, Timor‐Leste and Georgia: Strategic Lessons for Sub‐Saharan Africa
Background: Malaria remains a major cause of morbidity and mortality worldwide, with over 263 million cases and 597,000 deaths estimated in 2023, of which 94% occurred in Sub‐Saharan Africa. Despite this heavy burden, several low‐ and middle‐income countries have recently succeeded in eliminating local malaria transmission. Objective: This article describes and synthesises malaria elimination experiences in Suriname, Timor‐Leste and Georgia, all three certified malaria‐free by the World Health Organization in 2025, to identify strategic lessons and contextual factors that may inform elimination efforts in malaria‐endemic countries, including those in Sub‐Saharan Africa. Methodology: A structured narrative review was conducted using official reports from WHO, the Global Fund and PAHO; national public health documents; and peer‐reviewed articles indexed in PubMed, Scopus and Google Scholar between 2012 and 2025. Search terms included ‘malaria elimination,’ ‘malaria‐free certification,’ ‘Suriname malaria,’ ‘Timor‐Leste malaria’ and ‘Georgia malaria.’ Inclusion criteria required relevance to elimination strategies, publication in English or French and availability in full text. Grey literature from WHO, PAHO and the Global Fund was systematically included. Results: The three countries share several common determinants of success: strong and sustained political commitment, robust epidemiological surveillance systems, active community mobilisation and consistent financial support. Strategies were adapted to context: involvement of indigenous communities and cross‐border control in the Amazon basin (Suriname), universal coverage and extensive partner support in a postconflict setting (Timor‐Leste) and institutional resilience and postelimination vigilance in a context of political transition (Georgia). Conclusion: These experiences demonstrate that malaria elimination is achievable even in resource‐limited or fragile contexts, provided interventions are tailored to the local setting and supported by coherent governance. Key lessons for malaria‐endemic countries include strengthening community‐based surveillance, cross‐border cooperation, community education and securing sustainable financing. The risk of reintroduction remains real, and postelimination vigilance is essential.
- Open Access
- 30 October 2025
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 87 (12) , 7926-7927
Toward cancer immunoprevention: what are the prospects for therapeutic vaccines?
Therapeutic cancer vaccines represent a promising immunotherapy approach aimed at treating existing cancers by stimulating the patient’s immune system to target tumor cells. Unlike prophylactic vaccines, therapeutic vaccines are administered after cancer diagnosis and focus on inducing specific cytotoxic CD8 + T cell responses against tumor-associated antigens or tumor-specific neoantigens. These antigens are presented by antigen-presenting cells, such as dendritic cells, to activate an immune attack. However, the efficacy of therapeutic vaccines is often limited by immune tolerance, tumor heterogeneity, and an immunosuppressive tumor microenvironment, necessitating combination with other treatments like immune checkpoint inhibitors or chemotherapy. Multiple vaccine platforms are under investigation, including peptide/protein-based, DNA/messenger RNA (mRNA)-based, dendritic cell vaccines, viral vector vaccines, and personalized neoantigen vaccines that leverage next-generation sequencing for precision targeting. Clinical trials target a range of cancers, including melanoma, gynecologic, breast, pancreatic, liver, glioblastoma, and lung cancers, with results showing immune activation but modest clinical efficacy. Key challenges include immune evasion, variability in patient response, manufacturing complexities, high cost, and lack of predictive biomarkers. Technological advances in nanoparticle delivery, potent adjuvants, mRNA platforms, and combination immunotherapies are being explored to enhance vaccine performance. In low-resource settings, barriers such as limited access to advanced diagnostics and clinical trials necessitate tailored strategies to ensure equitable vaccine deployment. Overall, therapeutic cancer vaccines hold potential to become integrated into standard oncology protocols, especially for adjuvant therapy and recurrence prevention, with an emphasis on personalized and accessible immunotherapies to transform cancer management globally.
- 30 October 2025
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 87 (12) , 7926-7927
Open AccessToward cancer immunoprevention: what are the prospects for therapeutic vaccines?
Therapeutic cancer vaccines represent a promising immunotherapy approach aimed at treating existing cancers by stimulating the patient’s immune system to target tumor cells. Unlike prophylactic vaccines, therapeutic vaccines are administered after cancer diagnosis and focus on inducing specific cytotoxic CD8 + T cell responses against tumor-associated antigens or tumor-specific neoantigens. These antigens are presented by antigen-presenting cells, such as dendritic cells, to activate an immune attack. However, the efficacy of therapeutic vaccines is often limited by immune tolerance, tumor heterogeneity, and an immunosuppressive tumor microenvironment, necessitating combination with other treatments like immune checkpoint inhibitors or chemotherapy. Multiple vaccine platforms are under investigation, including peptide/protein-based, DNA/messenger RNA (mRNA)-based, dendritic cell vaccines, viral vector vaccines, and personalized neoantigen vaccines that leverage next-generation sequencing for precision targeting. Clinical trials target a range of cancers, including melanoma, gynecologic, breast, pancreatic, liver, glioblastoma, and lung cancers, with results showing immune activation but modest clinical efficacy. Key challenges include immune evasion, variability in patient response, manufacturing complexities, high cost, and lack of predictive biomarkers. Technological advances in nanoparticle delivery, potent adjuvants, mRNA platforms, and combination immunotherapies are being explored to enhance vaccine performance. In low-resource settings, barriers such as limited access to advanced diagnostics and clinical trials necessitate tailored strategies to ensure equitable vaccine deployment. Overall, therapeutic cancer vaccines hold potential to become integrated into standard oncology protocols, especially for adjuvant therapy and recurrence prevention, with an emphasis on personalized and accessible immunotherapies to transform cancer management globally.
- Open Access
- 27 October 2025
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 87 (12) , 7910-7911
Early cow’s milk consumption: a neglected factor in pediatric type 1 diabetes in sub-Saharan Africa
Type 1 diabetes (T1D), an insulin-dependent autoimmune disease, is silently progressing in sub-Saharan Africa but remains underrecognized and often diagnosed too late. Reported incidence rates (0.4–1.5 cases per 100 000 children per year) are likely underestimated due to the lack of national registries and high mortality resulting from limited access to insulin. Over 50% of children diagnosed with T1D in Nigeria, for example, die within 5 years. While international studies, such as the TRIGR study, have suggested an association between early cow’s milk exposure and pancreatic autoimmunity, this environmental risk factor remains largely unstudied in African contexts. Early cow’s milk introduction is common in sub-Saharan Africa due to socioeconomic pressures, maternal workload, and low exclusive breastfeeding rates, exposing infants to potential autoimmune triggers during a period of gut immaturity. Despite the growing burden of noncommunicable diseases, no national health policy in the region addresses this nutritional risk. This article calls for increased awareness, targeted research, and cost-effective preventive strategies including promotion of exclusive breastfeeding for 6 months, delayed introduction of cow’s milk, and health education. Addressing this gap is urgent to reduce preventable T1D-related morbidity and mortality in vulnerable populations across sub-Saharan Africa.
- 27 October 2025
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 87 (12) , 7910-7911
Open AccessEarly cow’s milk consumption: a neglected factor in pediatric type 1 diabetes in sub-Saharan Africa
Type 1 diabetes (T1D), an insulin-dependent autoimmune disease, is silently progressing in sub-Saharan Africa but remains underrecognized and often diagnosed too late. Reported incidence rates (0.4–1.5 cases per 100 000 children per year) are likely underestimated due to the lack of national registries and high mortality resulting from limited access to insulin. Over 50% of children diagnosed with T1D in Nigeria, for example, die within 5 years. While international studies, such as the TRIGR study, have suggested an association between early cow’s milk exposure and pancreatic autoimmunity, this environmental risk factor remains largely unstudied in African contexts. Early cow’s milk introduction is common in sub-Saharan Africa due to socioeconomic pressures, maternal workload, and low exclusive breastfeeding rates, exposing infants to potential autoimmune triggers during a period of gut immaturity. Despite the growing burden of noncommunicable diseases, no national health policy in the region addresses this nutritional risk. This article calls for increased awareness, targeted research, and cost-effective preventive strategies including promotion of exclusive breastfeeding for 6 months, delayed introduction of cow’s milk, and health education. Addressing this gap is urgent to reduce preventable T1D-related morbidity and mortality in vulnerable populations across sub-Saharan Africa.
- Open Access
- 9 October 2025
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 87 (12) , 7872-7874
Post-exposure prevention in Marburg virus outbreaks: potential role of remdesivir in emergency response
Marburg virus (MARV), a close relative of the Ebola virus, causes severe hemorrhagic fevers with a case fatality rate of up to 88%. In the absence of specific treatment or vaccine, its rapid spread through epidemics in Africa, particularly in Angola, DRC, Guinea, Uganda, and recently Tanzania, poses a major threat to global public health. The use of post-exposure prevention, already effective against viruses such as HIV and rabies, could offer a promising strategy to interrupt infection in recently exposed individuals. Remdesivir, a nucleotide analog initially developed against the Ebola virus and used for SARS-CoV-2, has shown significant antiviral activity against MARV in animal models. Administered within 24–48 hours of exposure, it reduces viral load and improves survival. This asymptomatic but active window of viral replication provides a valuable opportunity for intervention. Although clinical results are still lacking, preclinical data support urgent consideration of remdesivir as a rapid response tool. However, its logistical constraints (injectable form) limit its deployment in remote areas. Nevertheless, its integration into emergency protocols, accompanied by investments in research, early authorizations, and strategic stockpiles, could strengthen response capacities. While awaiting a vaccine, each antiviral option deserves rigorous attention to limit transmission and mortality during future Marburg outbreaks.
- 9 October 2025
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 87 (12) , 7872-7874
Open AccessPost-exposure prevention in Marburg virus outbreaks: potential role of remdesivir in emergency response
Marburg virus (MARV), a close relative of the Ebola virus, causes severe hemorrhagic fevers with a case fatality rate of up to 88%. In the absence of specific treatment or vaccine, its rapid spread through epidemics in Africa, particularly in Angola, DRC, Guinea, Uganda, and recently Tanzania, poses a major threat to global public health. The use of post-exposure prevention, already effective against viruses such as HIV and rabies, could offer a promising strategy to interrupt infection in recently exposed individuals. Remdesivir, a nucleotide analog initially developed against the Ebola virus and used for SARS-CoV-2, has shown significant antiviral activity against MARV in animal models. Administered within 24–48 hours of exposure, it reduces viral load and improves survival. This asymptomatic but active window of viral replication provides a valuable opportunity for intervention. Although clinical results are still lacking, preclinical data support urgent consideration of remdesivir as a rapid response tool. However, its logistical constraints (injectable form) limit its deployment in remote areas. Nevertheless, its integration into emergency protocols, accompanied by investments in research, early authorizations, and strategic stockpiles, could strengthen response capacities. While awaiting a vaccine, each antiviral option deserves rigorous attention to limit transmission and mortality during future Marburg outbreaks.
- Open Access
- 7 October 2025
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 87 (11) , 6959-6961
Impact of endocrine disruptors on female fertility: an update
Endocrine disruptors (EDs) are a heterogeneous group of natural or synthetic chemicals capable of interfering with hormonal regulation. Widely present in plastics, cosmetics, pesticides, food packaging, and household products, they contribute to constant human exposure. Compounds such as bisphenol A, phthalates, parabens, dioxins, and certain pesticides are among the most studied. Their mechanisms of action include interaction with hormone receptors, modulation of gene expression through epigenetic changes, disruption of steroidogenesis, and interference with the hypothalamic–pituitary–gonadal axis. Evidence from animal and human studies suggests that EDs may reduce ovarian reserve, impair oocyte maturation, alter ovulation and implantation, and contribute to infertility. Associations have also been observed with polycystic ovary syndrome, endometriosis, and poorer outcomes of assisted reproductive techniques. Despite these findings, human data remain largely observational, with methodological limitations such as variable exposure assessment, lack of standardized biomarkers, and the unaddressed “cocktail effect.” Strengthening preventive strategies, regulatory measures, and further research is essential to better understand and mitigate the risks EDs pose to female reproductive health.
- 7 October 2025
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 87 (11) , 6959-6961
Open AccessImpact of endocrine disruptors on female fertility: an update
Endocrine disruptors (EDs) are a heterogeneous group of natural or synthetic chemicals capable of interfering with hormonal regulation. Widely present in plastics, cosmetics, pesticides, food packaging, and household products, they contribute to constant human exposure. Compounds such as bisphenol A, phthalates, parabens, dioxins, and certain pesticides are among the most studied. Their mechanisms of action include interaction with hormone receptors, modulation of gene expression through epigenetic changes, disruption of steroidogenesis, and interference with the hypothalamic–pituitary–gonadal axis. Evidence from animal and human studies suggests that EDs may reduce ovarian reserve, impair oocyte maturation, alter ovulation and implantation, and contribute to infertility. Associations have also been observed with polycystic ovary syndrome, endometriosis, and poorer outcomes of assisted reproductive techniques. Despite these findings, human data remain largely observational, with methodological limitations such as variable exposure assessment, lack of standardized biomarkers, and the unaddressed “cocktail effect.” Strengthening preventive strategies, regulatory measures, and further research is essential to better understand and mitigate the risks EDs pose to female reproductive health.